Form Type: 4

SEC EDGAR Link
Accession Number:0000874015-19-000152
Date:2019-12-16
Issuer: IONIS PHARMACEUTICALS INC (IONS)
Original Submission Date:

Reporting Person:

KLEIN JOSEPH III
C/O IONIS PHARMACEUTICALS, INC.
2855 GAZELLE COURT CARLSBAD, CA 92010

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-12-16 M 1,000 a $35.53 13,683 direct
COMMON STOCK 2019-12-16 S 1,000 d $65.45 12,683 direct
COMMON STOCK 2019-12-16 0 $0.00 100 indirect
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
EMPLOYEE STOCK OPTION (RIGHT TO BUY) 35.53 2019-12-16 deemed execution date M 1,000 (d) 2018-07-01 2024-06-30 common stock 1,000 $35.53 1,000 direct
Footnotes
IDfootnote
f1 acquired as a result of exercising a stock option pursuant to rule 10b5-1 trading plan. the purchase and sale reported on this form 4 was effective pursuant to rule 10b5-1 trading plan adopted by the reporting person on 10/11/2019.
f2 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $63.78 to $66.135, inclusive. the reporting person undertakes to provide to ionis pharmaceuticals, inc., any security holder of ionis pharmaceuticals, inc. or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this form 4.
f3 represents the date on which the options are fully exercisable pursuant to the vesting schedule of the grant.
WhaleWisdom Logo

Elevate your investments